Please login to the form below

Not currently logged in
Email:
Password:

Eisai sets up new pharmaceutical marketing subsidiary in Belgium

Japanese pharmaceutical company, Eisai, has established its pharmaceutical marketing subsidiary, Eisai SA/NV in Belgium.

Japanese pharmaceutical company, Eisai, has established its pharmaceutical marketing subsidiary, Eisai SA/NV in Belgium.

Eisai SA/NV is owned by Eisai Europe and will serve as the regional sales centre for Benelux countries, the sixth largest market in the EU. The subsidiary will begin marketing activities in the region, focusing on the anti-epileptic drugs Zonegran (zonisamide) and Inovelon (rufinamide). It will also start to market the non-opioid severe chronic infused pain drug Prialt (ziconotide), while also co-promoting Alzheimer's disease treatment Aricept (donepezil) in Belgium and Luxembourg with its partner, Pfizer.

Eisai says it will further expand its business operations across the EU and will undertake independent marketing activities by using its own sales and marketing personnel, tailored for each county.

Eisai SA/NV is Eisai's ninth marketing subsidiary in the EU region, bringing the total number of countries where Eisai has sales and marketing operations through its own distribution channels to 17. These include the UK, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Belgium, Netherlands and Luxembourg.



28th September 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
TRIDUCIVE

Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....